EVIDENCE LIBRARY
Cannabidiol and Clobazam: An Epilepsy Review Separates Interaction From Independent Benefit
A cannabinoid review describes clobazam interaction as a possible contributor to both somnolence and apparent treatment benefit.
A cannabinoid review describes clobazam interaction as a possible contributor to both somnolence and apparent treatment benefit.
The metabolic context
The review discusses cannabidiol inhibition of CYP2C19 and its interaction with clobazam. It notes that combination treatment may contribute to adverse effects, particularly somnolence, while also potentially influencing observed seizure benefit. Trials of adjunct cannabidiol included patients receiving other antiseizure drugs.
Combination evidence needs careful attribution
An improvement during adjunct treatment does not automatically establish which component or interaction produced it. A narrative review also does not supply a single exposure increase applicable to every patient. Formulation, dose, feeding state, co-medication, and metabolite handling are relevant. The paper supports examining clobazam and metabolite exposure when interpreting sedation or response, rather than describing cannabidiol as pharmacologically separate from the background regimen. Its historical account of trials should not be treated as a current universal treatment recommendation.
Source paper
Original analysis of the supplied journal article, identified as PMC7012327.